Lysophosphatidic Acid: Promoter of Cancer Progression and of Tumor Microenvironment Development. A Promising Target for Anticancer Therapies?

Overview

Journal Cells

Publisher MDPI

Specialties Biochemistry
Biophysics
Cell Biology
Molecular Biology

Date 2021 Jul 2

PMID 34200030

Citations 18

Authors

Sistiana Aiello

Federica Casiraghi

Affiliations

Soon will be listed here.

Abstract

Increased expression of the enzyme autotaxin (ATX) and the consequently increased levels of its product, lysophosphatidic acid (LPA), have been reported in several primary tumors. The role of LPA as a direct modulator of tumor cell functions-motility, invasion and migration capabilities as well as resistance to apoptotic death-has been recognized by numerous studies over the last two decades. Notably, evidence has recently been accumulating that shows that LPA also contributes to the development of the tumor microenvironment (TME). Indeed, LPA plays a crucial role in inducing angiogenesis and lymphangiogenesis, triggering cellular glycolytic shift and stimulating intratumoral fibrosis. In addition, LPA helps tumoral cells to escape immune surveillance. Treatments that counter the TME components, in order to deprive cancer cells of their crucial support, have been emerging among the promising new anticancer therapies. This review aims to summarize the latest knowledge on how LPA influences both tumor cell functions and the TME by regulating the activity of its different elements, highlighting why and how LPA is worth considering as a molecular target for new anticancer therapies.

Citing Articles

Autotaxin-Lysophosphatidate Axis: Promoter of Cancer Development and Possible Therapeutic Implications.

Laface C, Ricci A, Vallarelli S, Ostuni C, Rizzo A, Ambrogio F Int J Mol Sci. 2024; 25(14).

PMID: 39062979 PMC: 11277072. DOI: 10.3390/ijms25147737.

Phosphoproteomics Reveals Selective Regulation of Signaling Pathways by Lysophosphatidic Acid Species in Macrophages.

Dietze R, Szymanski W, Ojasalu K, Finkernagel F, Nist A, Stiewe T Cells. 2024; 13(10.

PMID: 38786034 PMC: 11119170. DOI: 10.3390/cells13100810.

First insight about the ability of specific glycerophospholipids to discriminate non-small cell lung cancer subtypes.

Sieminska J, Miniewska K, Mroz R, Sierko E, Naumnik W, Kisluk J Front Mol Biosci. 2024; 11:1379631.

PMID: 38725870 PMC: 11079276. DOI: 10.3389/fmolb.2024.1379631.

Lysophosphatidic acid down-regulates human RIPK4 mRNA in keratinocyte- derived cell lines.

Xu L, Bajorski P, Poligone B PLoS One. 2024; 19(4):e0287444.

PMID: 38630705 PMC: 11023271. DOI: 10.1371/journal.pone.0287444.

Role for CCN1 in lysophosphatidic acid response in PC-3 human prostate cancer cells.

Balijepalli P, Knode B, Nahulu S, Abrahamson E, Nivison M, Meier K J Cell Commun Signal. 2024; 18(1):e12019.

PMID: 38545253 PMC: 10964937. DOI: 10.1002/ccs3.12019.

References

Piersma B, Hayward M, Weaver V . Fibrosis and cancer: A strained relationship. Biochim Biophys Acta Rev Cancer. 2020; 1873(2):188356. PMC: 7733542. DOI: 10.1016/j.bbcan.2020.188356. View

Oikonomou N, Mouratis M, Tzouvelekis A, Kaffe E, Valavanis C, Vilaras G . Pulmonary autotaxin expression contributes to the pathogenesis of pulmonary fibrosis. Am J Respir Cell Mol Biol. 2012; 47(5):566-74. DOI: 10.1165/rcmb.2012-0004OC. View

Schafer M, Werner S . Cancer as an overhealing wound: an old hypothesis revisited. Nat Rev Mol Cell Biol. 2008; 9(8):628-38. DOI: 10.1038/nrm2455. View

Oda S, Strauch P, Fujiwara Y, Al-Shami A, Oravecz T, Tigyi G . Lysophosphatidic acid inhibits CD8 T cell activation and control of tumor progression. Cancer Immunol Res. 2014; 1(4):245-55. PMC: 3893823. DOI: 10.1158/2326-6066.CIR-13-0043-T. View

Aoki J, Inoue A, Okudaira S . Two pathways for lysophosphatidic acid production. Biochim Biophys Acta. 2008; 1781(9):513-8. DOI: 10.1016/j.bbalip.2008.06.005. View

Benesch M, Zhao Y, Curtis J, McMullen T, Brindley D . Regulation of autotaxin expression and secretion by lysophosphatidate and sphingosine 1-phosphate. J Lipid Res. 2015; 56(6):1134-44. PMC: 4442871. DOI: 10.1194/jlr.M057661. View

Kehlen A, Englert N, Seifert A, Klonisch T, Dralle H, Langner J . Expression, regulation and function of autotaxin in thyroid carcinomas. Int J Cancer. 2004; 109(6):833-8. DOI: 10.1002/ijc.20022. View

Jin M, Jin W . The updated landscape of tumor microenvironment and drug repurposing. Signal Transduct Target Ther. 2020; 5(1):166. PMC: 7447642. DOI: 10.1038/s41392-020-00280-x. View

Maher T, van der Aar E, Van de Steen O, Allamassey L, Desrivot J, Dupont S . Safety, tolerability, pharmacokinetics, and pharmacodynamics of GLPG1690, a novel autotaxin inhibitor, to treat idiopathic pulmonary fibrosis (FLORA): a phase 2a randomised placebo-controlled trial. Lancet Respir Med. 2018; 6(8):627-635. DOI: 10.1016/S2213-2600(18)30181-4. View

10.

Hozumi H, Hokari R, Kurihara C, Narimatsu K, Sato H, Sato S . Involvement of autotaxin/lysophospholipase D expression in intestinal vessels in aggravation of intestinal damage through lymphocyte migration. Lab Invest. 2013; 93(5):508-19. DOI: 10.1038/labinvest.2013.45. View

11.

King C, Nathan S . Idiopathic pulmonary fibrosis: effects and optimal management of comorbidities. Lancet Respir Med. 2016; 5(1):72-84. DOI: 10.1016/S2213-2600(16)30222-3. View

12.

Hama K, Aoki J, Fukaya M, Kishi Y, Sakai T, Suzuki R . Lysophosphatidic acid and autotaxin stimulate cell motility of neoplastic and non-neoplastic cells through LPA1. J Biol Chem. 2004; 279(17):17634-9. DOI: 10.1074/jbc.M313927200. View

13.

Bain G, Shannon K, Huang F, Darlington J, Goulet L, Prodanovich P . Selective Inhibition of Autotaxin Is Efficacious in Mouse Models of Liver Fibrosis. J Pharmacol Exp Ther. 2016; 360(1):1-13. DOI: 10.1124/jpet.116.237156. View

14.

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

15.

Cadamuro M, Nardo G, Indraccolo S, DallOlmo L, Sambado L, Moserle L . Platelet-derived growth factor-D and Rho GTPases regulate recruitment of cancer-associated fibroblasts in cholangiocarcinoma. Hepatology. 2013; 58(3):1042-53. PMC: 3732815. DOI: 10.1002/hep.26384. View

16.

Tang X, Benesch M, Brindley D . Lipid phosphate phosphatases and their roles in mammalian physiology and pathology. J Lipid Res. 2015; 56(11):2048-60. PMC: 4617392. DOI: 10.1194/jlr.R058362. View

17.

Tang X, Zhao Y, Dewald J, Curtis J, Brindley D . Tetracyclines increase lipid phosphate phosphatase expression on plasma membranes and turnover of plasma lysophosphatidate. J Lipid Res. 2016; 57(4):597-606. PMC: 4808768. DOI: 10.1194/jlr.M065086. View

18.

Swaney J, Chapman C, Correa L, Stebbins K, Bundey R, Prodanovich P . A novel, orally active LPA(1) receptor antagonist inhibits lung fibrosis in the mouse bleomycin model. Br J Pharmacol. 2010; 160(7):1699-713. PMC: 2936842. DOI: 10.1111/j.1476-5381.2010.00828.x. View

19.

Budhwar S, Verma P, Verma R, Rai S, Singh K . The Yin and Yang of Myeloid Derived Suppressor Cells. Front Immunol. 2018; 9:2776. PMC: 6280921. DOI: 10.3389/fimmu.2018.02776. View

20.

Contos J, Ishii I, Chun J . Lysophosphatidic acid receptors. Mol Pharmacol. 2000; 58(6):1188-96. DOI: 10.1124/mol.58.6.1188. View